Published in Neurol Res Int on September 22, 2011
Multiple sclerosis, relapses, and the mechanism of action of adrenocorticotropic hormone. Front Neurol (2013) 0.83
What do effective treatments for multiple sclerosis tell us about the molecular mechanisms involved in pathogenesis? Int J Mol Sci (2012) 0.81
Need for a paradigm shift in therapeutic approaches to CNS injury. Expert Rev Neurother (2012) 0.80
Serum autoantibodies to myelin peptides distinguish acute disseminated encephalomyelitis from relapsing-remitting multiple sclerosis. Mult Scler (2013) 0.80
Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis. Expert Opin Biol Ther (2016) 0.78
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med (2008) 12.90
IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med (2005) 10.39
Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol (2000) 9.73
IgG Fc receptors. Annu Rev Immunol (2001) 8.63
B cells regulate autoimmunity by provision of IL-10. Nat Immunol (2002) 7.30
Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA (2006) 7.09
Evidence-based guideline update: Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology (2011) 7.09
AN ELECTROPHORETIC STUDY OF THE PROTEIN COMPONENTS IN CEREBROSPINAL FLUID AND THEIR RELATIONSHIP TO THE SERUM PROTEINS. J Clin Invest (1942) 6.90
Multiple sclerosis--the plaque and its pathogenesis. N Engl J Med (2006) 6.60
Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology (2007) 3.83
Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med (1999) 3.66
Natural autoantibodies: from 'horror autotoxicus' to 'gnothi seauton'. Immunol Today (1991) 3.35
An open label study of the effects of rituximab in neuromyelitis optica. Neurology (2005) 2.99
A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol (1999) 2.69
Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol (2007) 2.68
Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet (2005) 2.68
Mast cells are essential for early onset and severe disease in a murine model of multiple sclerosis. J Exp Med (2000) 2.54
Management of antiphospholipid antibody syndrome: a systematic review. JAMA (2006) 2.47
Myelin impairs CNS remyelination by inhibiting oligodendrocyte precursor cell differentiation. J Neurosci (2006) 2.44
Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology (2002) 2.41
Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis. Ann Neurol (2006) 2.33
Immunoglobulins promote remyelination in the central nervous system. Ann Neurol (1990) 2.27
Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med (2001) 2.27
Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J Exp Med (2008) 2.26
On the epidemiology of influenza. Virol J (2008) 2.17
Dendritic cell modulation by 1alpha,25 dihydroxyvitamin D3 and its analogs: a vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc Natl Acad Sci U S A (2001) 2.14
Immunohistochemical study of allergic encephalomyelitis. Am J Pathol (1968) 2.10
Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol (2006) 2.06
B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions. J Immunol (1999) 2.06
Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects. Neurology (2004) 2.04
Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann Neurol (2010) 1.97
Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. J Clin Invest (2005) 1.95
Clonal expansion and somatic hypermutation of V(H) genes of B cells from cerebrospinal fluid in multiple sclerosis. J Clin Invest (1998) 1.95
Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J Neurol (2007) 1.92
Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. Proc Natl Acad Sci U S A (2004) 1.91
Demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesions: a case for antigen-specific antibody mediation. Ann Neurol (1999) 1.77
Accumulation of clonally related B lymphocytes in the cerebrospinal fluid of multiple sclerosis patients. J Immunol (2000) 1.64
Vitamin D receptor: molecular signaling and actions of nutritional ligands in disease prevention. Nutr Rev (2008) 1.62
The demyelinating potential of antibodies to myelin oligodendrocyte glycoprotein is related to their ability to fix complement. Am J Pathol (1993) 1.59
Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult Scler (2008) 1.58
Temporal invariance and clonal uniformity of brain and cerebrospinal IgG, IgA, and IgM in multiple sclerosis. J Exp Med (1986) 1.56
Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination. Ann Neurol (1998) 1.56
Molecular nature of the vitamin D receptor and its role in regulation of gene expression. Rev Endocr Metab Disord (2001) 1.55
Immunoadsorption patients with multiple sclerosis: an open-label pilot study. Eur J Clin Invest (2005) 1.50
Vitamin D status is positively correlated with regulatory T cell function in patients with multiple sclerosis. PLoS One (2009) 1.50
THE APPLICATION OF TISSUE CULTURE TO THE STUDY OF EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS. II. SERUM FACTORS RESPONSIBLE FOR DEMYELINATION. J Exp Med (1964) 1.49
Evidence for genetic regulation of vitamin D status in twins with multiple sclerosis. Am J Clin Nutr (2008) 1.49
Beneficial plasma exchange response in central nervous system inflammatory demyelination. Arch Neurol (2011) 1.49
Vitamin D and autoimmunity: is vitamin D status an environmental factor affecting autoimmune disease prevalence? Proc Soc Exp Biol Med (2000) 1.48
Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis. Proc Natl Acad Sci U S A (2000) 1.46
A longitudinal study of serum 25-hydroxyvitamin D and intact parathyroid hormone levels indicate the importance of vitamin D and calcium homeostasis regulation in multiple sclerosis. J Neurol Neurosurg Psychiatry (2007) 1.46
Antibodies from inflamed central nervous system tissue recognize myelin oligodendrocyte glycoprotein. J Immunol (2005) 1.43
Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. J Clin Invest (2005) 1.41
The relevance of animal models in multiple sclerosis research. Pathophysiology (2011) 1.40
Vitamin D and its analogs as regulators of immune activation and antigen presentation. Annu Rev Nutr (2003) 1.38
Prevalence of vitamin D deficiency and its relationship with thyroid autoimmunity in Asian Indians: a community-based survey. Br J Nutr (2009) 1.37
An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis. PLoS One (2010) 1.36
Multiple sclerosis after infectious mononucleosis. Arch Neurol (2007) 1.34
Effects of 1alpha,25(OH)2D3 and its analogs on dendritic cell function. J Cell Biochem (2003) 1.32
CSF oligoclonal band status informs prognosis in multiple sclerosis: a case control study of 100 patients. J Neurol Neurosurg Psychiatry (2008) 1.32
Patterns of cerebrospinal fluid pathology correlate with disease progression in multiple sclerosis. Brain (2001) 1.30
The geographic distribution of multiple sclerosis: a review. Neuroepidemiology (1993) 1.30
Isoelectric focusing of IgG eluted from multiple sclerosis and subacute sclerosing panencephalitis brains. Nature (1980) 1.28
Autoantibodies to myelin basic protein catalyze site-specific degradation of their antigen. Proc Natl Acad Sci U S A (2005) 1.28
Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol (2009) 1.27
Estimated benefit of increased vitamin D status in reducing the economic burden of disease in western Europe. Prog Biophys Mol Biol (2009) 1.26
Multiple sclerosis: a quantitative and qualitative study of immunoglobulin-containing cells in the central nervous system. Neuropathol Appl Neurobiol (1980) 1.26
Vitamin D and multiple sclerosis: an update. Nutr Rev (2008) 1.25
Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol (2006) 1.23
Vitamin D receptor: key roles in bone mineral pathophysiology, molecular mechanism of action, and novel nutritional ligands. J Bone Miner Res (2007) 1.22
Potent inhibition of dendritic cell differentiation and maturation by vitamin D analogs. Biochem Biophys Res Commun (2000) 1.21
Recognition of the immunodominant myelin basic protein peptide by autoantibodies and HLA-DR2-restricted T cell clones from multiple sclerosis patients. Identity of key contact residues in the B-cell and T-cell epitopes. J Clin Invest (1997) 1.21
Recognition and degradation of myelin basic protein peptides by serum autoantibodies: novel biomarker for multiple sclerosis. J Immunol (2008) 1.21
Higher levels of 25-hydroxyvitamin D are associated with a lower incidence of multiple sclerosis only in women. Mult Scler (2008) 1.19
Involvement of Fc receptors in disorders of the central nervous system. Neuromolecular Med (2009) 1.15
A recombinant human IgM promotes myelin repair after a single, very low dose. J Neurosci Res (2007) 1.15
Remyelination-promoting antibodies activate distinct Ca2+ influx pathways in astrocytes and oligodendrocytes: relationship to the mechanism of myelin repair. Mol Cell Neurosci (2003) 1.14
The relevance of vitamin D receptor gene polymorphisms for vitamin D research in multiple sclerosis. Autoimmun Rev (2009) 1.12
Antibodies to glycosphingolipids in patients with multiple sclerosis and SLE. J Immunol (1984) 1.12
Multiple sclerosis and Alzheimer's disease. Ann Neurol (2008) 1.11
Immunoglobulins stimulate central nervous system remyelination: electron microscopic and morphometric analysis of proliferating cells. Lab Invest (1991) 1.10
Targeting of IgMkappa antibodies to oligodendrocytes promotes CNS remyelination. J Neurosci (1998) 1.10
Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain-Barré syndrome. BMC Health Serv Res (2011) 1.09
A human antibody that promotes remyelination enters the CNS and decreases lesion load as detected by T2-weighted spinal cord MRI in a virus-induced murine model of MS. FASEB J (2004) 1.08
Neuron-binding human monoclonal antibodies support central nervous system neurite extension. J Neuropathol Exp Neurol (2004) 1.08
Elevated levels of antibody to myelin oligodendrocyte glycoprotein is not specific for patients with multiple sclerosis. Arch Neurol (1999) 1.06
Human antibodies accelerate the rate of remyelination following lysolecithin-induced demyelination in mice. Glia (2002) 1.06
Fok-I vitamin D receptor gene polymorphism (rs10735810) and vitamin D metabolism in multiple sclerosis. J Neuroimmunol (2009) 1.05
Antigen-dependent intrathecal antibody synthesis in the normal rat brain: tissue entry and local retention of antigen-specific B cells. J Immunol (1998) 1.05
Multiple sclerosis and vitamin D: an update. Eur J Clin Nutr (2004) 1.05
Relationship of UV exposure to prevalence of multiple sclerosis in England. Neurology (2011) 1.05
Direct evidence that a human antibody derived from patient serum can promote myelin repair in a mouse model of chronic-progressive demyelinating disease. FASEB J (2002) 1.04
Metabolism of 1,25-dihydroxyvitamin D3. Physiol Rev (1984) 1.03
Vitamin D receptor-mediated suppression of RelB in antigen presenting cells: a paradigm for ligand-augmented negative transcriptional regulation. Arch Biochem Biophys (2007) 1.02
Remyelination by oligodendrocytes stimulated by antiserum to spinal cord. J Neuropathol Exp Neurol (1987) 1.01
Catalytic antibodies in clinical and experimental pathology: human and mouse models. J Immunol Methods (2002) 1.01
Multiple sclerosis after infectious mononucleosis: record linkage study. J Epidemiol Community Health (2004) 1.00
Antibodies to peripheral nerve myelin may occur without clinical neuropathy in healthy persons. J Neuroimmunol (1991) 1.00
A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology (2001) 1.00
Antiapoptotic signaling by a remyelination-promoting human antimyelin antibody. Neurobiol Dis (2004) 0.99
Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS). Brain (2010) 4.77
Transfusion-related acute lung injury in the critically ill: prospective nested case-control study. Am J Respir Crit Care Med (2007) 3.69
Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher (2010) 3.47
Transfusion-related acute lung injury: incidence and risk factors. Blood (2011) 3.12
Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. J Clin Apher (2013) 2.97
Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet (2005) 2.68
Not every patient with multiple sclerosis should be treated at time of diagnosis. Arch Neurol (2006) 2.67
[(18)F]-fluorodeoxyglucose-positron emission tomography in patients with active myelopathy. Mayo Clin Proc (2013) 2.64
Fresh red blood cell transfusion and short-term pulmonary, immunologic, and coagulation status: a randomized clinical trial. Am J Respir Crit Care Med (2012) 2.47
Transfusion-related acute lung injury and pulmonary edema in critically ill patients: a retrospective study. Transfusion (2006) 2.45
Evidence-based red cell transfusion in the critically ill: quality improvement using computerized physician order entry. Crit Care Med (2006) 2.44
Quality of life is favorable for most patients with multiple sclerosis: a population-based cohort study. Arch Neurol (2004) 2.37
Multiple sclerosis, brain radiotherapy, and risk of neurotoxicity: the Mayo Clinic experience. Int J Radiat Oncol Biol Phys (2006) 2.12
Fresh-frozen plasma and platelet transfusions are associated with development of acute lung injury in critically ill medical patients. Chest (2007) 2.11
A novel source of viable peripheral blood mononuclear cells from leukoreduction system chambers. Transfusion (2006) 2.04
Transfusion from male-only versus female donors in critically ill recipients of high plasma volume components. Crit Care Med (2007) 1.79
Retracted Cross-linking the B7 family molecule B7-DC directly activates immune functions of dendritic cells. J Exp Med (2002) 1.68
Multiple sclerosis therapies in pediatric patients with refractory multiple sclerosis. Arch Neurol (2010) 1.61
Paraneoplastic jaw dystonia and laryngospasm with antineuronal nuclear autoantibody type 2 (anti-Ri). Arch Neurol (2010) 1.60
Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. J Am Soc Nephrol (2011) 1.57
Antibody-mediated rejection despite inhibition of terminal complement. Transpl Int (2014) 1.52
The effect of double- and triple-apheresis platelet product donation on apheresis donor platelet and white blood cell counts. Transfusion (2008) 1.49
Solitary sclerosis: progressive myelopathy from solitary demyelinating lesion. Neurology (2012) 1.49
Beneficial plasma exchange response in central nervous system inflammatory demyelination. Arch Neurol (2011) 1.49
The relevance of animal models in multiple sclerosis research. Pathophysiology (2011) 1.40
Guidelines on the use of therapeutic apheresis in clinical practice: evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher (2007) 1.38
Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study. Biol Blood Marrow Transplant (2008) 1.37
Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study. Ann Neurol (2004) 1.36
American society for apheresis guidelines support use of red cell exchange transfusion for severe malaria with high parasitemia. Clin Infect Dis (2013) 1.29
Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol (2009) 1.27
Absence of perforin expression confers axonal protection despite demyelination. Neurobiol Dis (2006) 1.26
Retracted Immunotherapeutic potential of B7-DC (PD-L2) cross-linking antibody in conferring antitumor immunity. Cancer Res (2004) 1.26
Clearance of Theiler's virus infection depends on the ability to generate a CD8+ T cell response against a single immunodominant viral peptide. Eur J Immunol (2003) 1.25
Retracted Naturally occurring human IgM antibody that binds B7-DC and potentiates T cell stimulation by dendritic cells. J Immunol (2003) 1.21
Apoptosis of hippocampal pyramidal neurons is virus independent in a mouse model of acute neurovirulent picornavirus infection. Am J Pathol (2009) 1.19
Transient Receptor Potential Vanilloid 1 is essential for cisplatin-induced heat hyperalgesia in mice. Mol Pain (2010) 1.19
Surface plasmon resonance for high-throughput ligand screening of membrane-bound proteins. Biotechnol J (2009) 1.15
A recombinant human IgM promotes myelin repair after a single, very low dose. J Neurosci Res (2007) 1.15
Interleukin-6 protects anterior horn neurons from lethal virus-induced injury. J Neurosci (2003) 1.15
Seizures in patients with multiple sclerosis: epidemiology, pathophysiology and management. CNS Drugs (2009) 1.14
Remyelination-promoting antibodies activate distinct Ca2+ influx pathways in astrocytes and oligodendrocytes: relationship to the mechanism of myelin repair. Mol Cell Neurosci (2003) 1.14
CD8+ T cells directed against a viral peptide contribute to loss of motor function by disrupting axonal transport in a viral model of fulminant demyelination. J Neuroimmunol (2007) 1.12
Prospective study on the clinical course and outcomes in transfusion-related acute lung injury*. Crit Care Med (2014) 1.11
Efficient central nervous system remyelination requires T cells. Ann Neurol (2003) 1.11
Clinical outcomes and mechanism of action for rheopheresis treatment of age-related macular degeneration (AMD). J Clin Apher (2005) 1.11
Antigen-specific CD8+ T cells mediate a peptide-induced fatal syndrome. J Immunol (2005) 1.09
Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune-mediated severe ADAMTS13-deficiency: a report of four cases and a systematic review of the literature. Eur J Haematol (2009) 1.09
Retracted Blockade of allergic airway inflammation following systemic treatment with a B7-dendritic cell (PD-L2) cross-linking human antibody. J Immunol (2004) 1.09
A human antibody that promotes remyelination enters the CNS and decreases lesion load as detected by T2-weighted spinal cord MRI in a virus-induced murine model of MS. FASEB J (2004) 1.08
Neuron-binding human monoclonal antibodies support central nervous system neurite extension. J Neuropathol Exp Neurol (2004) 1.08
Gait apraxia in multiple sclerosis. Can J Neurol Sci (2009) 1.07
Sporadic leucodystrophy with neuroaxonal spheroids: persistence of DWI changes and neurocognitive profiles: a case study. J Neurol Neurosurg Psychiatry (2010) 1.07
Acute hemorrhagic demyelination in a murine model of multiple sclerosis. J Neuroinflammation (2008) 1.07
Demyelinated axons and motor function are protected by genetic deletion of perforin in a mouse model of multiple sclerosis. J Neuropathol Exp Neurol (2009) 1.06
Ticlopidine-, clopidogrel-, and prasugrel-associated thrombotic thrombocytopenic purpura: a 20-year review from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost (2012) 1.06
Human antibodies accelerate the rate of remyelination following lysolecithin-induced demyelination in mice. Glia (2002) 1.06
Kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegeneration. Biol Chem (2008) 1.06
REM sleep behavior disorder initiated by acute brainstem multiple sclerosis. Neurology (2006) 1.05
HLA DR and DQ interaction in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis in HLA class II transgenic mice. J Neuroimmunol (2005) 1.04
Cognitive impairment occurs in children and adolescents with multiple sclerosis: results from a United States network. J Child Neurol (2012) 1.04
The potential role of plasma exchange as a treatment for bilateral diffuse uveal melanocytic proliferation: a report of two cases. J Clin Apher (2011) 1.04
Identification of T cell epitopes on human proteolipid protein and induction of experimental autoimmune encephalomyelitis in HLA class II-transgenic mice. Eur J Immunol (2004) 1.04
Direct evidence that a human antibody derived from patient serum can promote myelin repair in a mouse model of chronic-progressive demyelinating disease. FASEB J (2002) 1.04
Disrupted spatial memory is a consequence of picornavirus infection. Neurobiol Dis (2006) 1.04
Enzymatic properties of rat myelencephalon-specific protease. Biochemistry (2002) 1.03
Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis. Mult Scler (2012) 1.01
Targeting kallikrein 6 proteolysis attenuates CNS inflammatory disease. FASEB J (2004) 1.01
A 54-year-old man with slowness of movement and confusion. Neurology (2007) 1.01
Later-onset Fabry disease: an adult variant presenting with the cramp-fasciculation syndrome. Arch Neurol (2006) 1.01
Thrombotic thrombocytopenic purpura: 2012 American Society for Apheresis (ASFA) consensus conference on classification, diagnosis, management, and future research. J Clin Apher (2013) 1.00
Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989-2008). Kidney Int Suppl (2009) 1.00
CD8+ T cells cause disability and axon loss in a mouse model of multiple sclerosis. PLoS One (2010) 0.99
Antiapoptotic signaling by a remyelination-promoting human antimyelin antibody. Neurobiol Dis (2004) 0.99
Prevalence of tremor in multiple sclerosis and associated disability in the Olmsted County population. Mov Disord (2004) 0.99
Brainstem 1H nuclear magnetic resonance (NMR) spectroscopy: marker of demyelination and repair in spinal cord. Ann Neurol (2009) 0.98
Differential protein expression in male and female human lumbar cerebrospinal fluid using iTRAQ reagents after abundant protein depletion. Proteomics (2007) 0.97
Magnetic resonance imaging, microscopy, and spectroscopy of the central nervous system in experimental animals. NeuroRx (2005) 0.97
Cancer-associated microangiopathic hemolytic anemia with thrombocytopenia: an important diagnostic consideration. Eur J Haematol (2010) 0.97
Multiple sclerosis with predominant, severe cognitive impairment. Arch Neurol (2009) 0.97
Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization. Biol Blood Marrow Transplant (2012) 0.95
Facile assembly of micro- and nanoarrays for sensing with natural cell membranes. ACS Nano (2011) 0.95